spacer
home > ebr > autumn 2017 > risk ratio
PUBLICATIONS
European Biopharmaceutical Review

Risk Ratio

On 30 August 2017, the US FDA formally approved the application for Kymriah, a cancer immunotherapy utilising modified human T-cells that express chimeric antigen receptors (CAR-T). This momentous event follows a decade of intense work to commercialise a therapy that was first demonstrated in 2011 in a handful of terminal paediatric leukaemia patients. At this moment, many CAR variants are in development, alongside a biotechnology business frenzy.

Pre-genomic immunotherapy consisted of human immunoglobulin injections to boost immunity during disease outbreaks. Clearly, this was a blunt instrument. Half a century later, a group at the University of Pennsylvania described remission in paediatric patients with refractory chronic lymphocytic leukaemia using genetically modified immune cells. Furthermore, at the beginning of September 2017, the first ever approval of CAR-T therapy was granted by the FDA for cases of acute lymphoblastic leukaemia in children and young adults. This inverts the usual regulatory paradigm by approving paediatric indications first.

In their Harvard Business Review paper ‘How to Spot a Technological Winner’, Graham and White discuss the factors that influence the success of a transformative innovation. The present intensity of the commercial race in cancer immunotherapy and gene-editing reflects a belief within the biopharmaceutical community that the trade-off of business drivers and technical hurdles is favourable. In just a few years, the number of groups working in this field has expanded from just a handful to over 200.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board and an industry consultant with experience in drug discovery, development and pharmaceutical outsourcing.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Release of Joint White Paper with Domino on Ink Leachability in Pharmaceutical Serialization

Philadelphia, PA – September 20, 2017 – Leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the release of a published white paper detailing Domino’s study which analyzes potential leachability of ink from coding technologies used in pharmaceutical Serialization activities.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

INTERPHEX 2018

17-18 April 2018, Javits Center, New York, USA

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA).
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement